Real-life use of onabotulinumtoxinA for symptom relief in patients with chronic migraine: REPOSE study methodology and baseline data

Table 3 Disease History of Patients with CM

		6-Month Completers (n = 336)
Time since first diagnosis of CM, years	N	336
	Mean (SD)	5.1 (7.6)
	Median (min, max)	1.8 (−0.8, 40.6)^a
Age of onset, years^b	N	331
	Mean (SD)	18.5 (9.3)
	Median (min, max)	16 (3, 57)
Time since first diagnosis of migraine, years	N	330
	Mean (SD)	19.5 (12.1)
	Median (min, max)	19.8 (−0.2, 71)^a
Non-CM headache diagnoses, n (%)^d	Migraine	245 (72.9)
	Medication overuse^c	115 (34.2)
	Tension headache	83 (24.7)
	Chronic tension-type headache	41 (12.2)
	Chronic daily headache	39 (11.6)
	Menstrual headache or menstrual migraine	28 (8.3)
	Stress headache	28 (8.3)
	Intractable/refractory migraine or headache	21 (6.3)
	Cluster headache	8 (2.4)
	Sinus headache	4 (1.2)
	Hemicrania continua	1 (0.3)
	New daily persistent headache	0
	Other	5 (1.5)

CM = chronic migraine
^aThe negative minimum value results from incorrect dates in the electronic case report form. The date of the baseline visit was prior to the date of the first diagnosis in 1 patient
^bBased on the patient’s recollection
^cIncludes any diagnosis of medication overuse, rebound, or analgesic overuse headache, based on the treating physician’s clinical judgment
^dMultiple answers were possible

ISSN: 1129-2377